ALSO NOTED: Visiomed, Clinical Cell Culture to merge; Genzyme wants to reopen merger vote; Vical touts adjuvant data; and much

> Visiomed Group and Clinical Cell Culture are merging into a $27 million biotech company. Release

> Bioenvision and Genzyme want to reopen the vote on a proposed merger, despite the opposition of a big shareholder. Release

> Vical announced that data from a study in mice demonstrated the potential of its patented Vaxfectin adjuvant to be used as a dose-sparing agent with a protein-based H5N1 pandemic influenza vaccine. Release

> Roche is still confident that the company's $3 billion takeover bid for Ventana will be accepted. Report

> What do you call a migraine drug that could help alcoholics quit drinking? A big-time marketing opportunity--if it weren't going off patent next year. Report

> Say the Pfizer/Sanofi-Aventis rumors are true: Would merging with the French drug maker boost Pfizer's fortunes? Not so much, say some observers. Report

And Finally... A team of Australian scientists has found an enzyme in diabetics that prevents them from producing insulin. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.